Axecap Investments LLC Purchases Shares of 1,994 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Axecap Investments LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,994 shares of the biopharmaceutical company’s stock, valued at approximately $2,096,000.

A number of other large investors have also added to or reduced their stakes in the company. Gateway Investment Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 13.7% in the first quarter. Gateway Investment Advisers LLC now owns 1,337 shares of the biopharmaceutical company’s stock worth $1,287,000 after buying an additional 161 shares during the period. Wealthcare Advisory Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 14.4% in the first quarter. Wealthcare Advisory Partners LLC now owns 294 shares of the biopharmaceutical company’s stock worth $283,000 after buying an additional 37 shares during the period. Janiczek Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 20.1% in the first quarter. Janiczek Wealth Management LLC now owns 221 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 37 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Regeneron Pharmaceuticals by 11.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 23,151 shares of the biopharmaceutical company’s stock worth $22,283,000 after buying an additional 2,412 shares during the period. Finally, 180 Wealth Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $218,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on REGN. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Royal Bank of Canada restated an “outperform” rating and set a $1,260.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday. Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Leerink Partners restated a “market perform” rating and set a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,102.19.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $941.39 on Thursday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average price is $1,098.29 and its 200-day moving average price is $1,040.67. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20. The stock has a market cap of $103.73 billion, a P/E ratio of 27.81, a P/E/G ratio of 3.40 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $8.79 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.6 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.